The diagnostic power of CD117, CD13, CD56, CD64, and MPO in rapid screening acute promyelocytic leukemia
- PDF / 1,348,235 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 63 Downloads / 180 Views
BMC Research Notes Open Access
RESEARCH NOTE
The diagnostic power of CD117, CD13, CD56, CD64, and MPO in rapid screening acute promyelocytic leukemia Vinh Thanh Tran1†, Thang Thanh Phan1*† , Hong‑Phuoc Mac2,3†, Tung Thanh Tran2, Toan Trong Ho1, Suong Phuoc Pho1, Van‑Anh Ngoc Nguyen1, Truc‑My Vo1, Hue Thi Nguyen1, Thao Thi Le1, Tin Huu Vo2 and Son Truong Nguyen4†
Abstract Objective: The same immuno-phenotype between HLA-DR-negative acute myeloid leukemia (AML) and acute pro‑ myelocytic leukemia (APL) causes APL rapid screening to become difficult. This study aimed to identify the associated antigens for APL and the best model in clinical uses. Results: A total of 36 APL (PML–RARA+) and 29 HLA-DR-negative non-APL patients enrolled in this study. When a cut-off point of 20% events was applied to define positive or negative status, APL and non-APL patients share a similar immuno-phenotype of CD117, CD34, CD11b, CD13, CD33, and MPO (P > 0.05). However, expression intensity of CD117 (P = 0.002), CD13 (P
Data Loading...
